Is Becoming an FNP Worth It?

An ACT score of 15 or lower signifies very poorly controlled asthma. However, stepping up pharmacotherapy is only valid if the patient is actually taking their current regimen. Because this patient is missing doses due to financial barriers, the primary intervention must address medication adherence by finding a cost-effective alternative. Prescribing a high-dose ICS-LABA combination inhaler will likely cost more and fail to resolve the underlying adherence issue. Adding a long-acting muscarinic antagonist unnecessarily complicates the regimen and increases the financial burden. Initiating a daily oral corticosteroid maintenance regimen is inappropriate for chronic management without first maximizing inhaled therapies through consistent, affordable adherence.

Peripheral edema is a very common, dose-dependent side effect of dihydropyridine calcium channel blockers like amlodipine. This occurs because the medication causes preferential precapillary vasodilation, which increases capillary hydrostatic pressure and forces fluid into the interstitial space, rather than causing systemic volume overload. Because the patient's lungs are clear and there is no jugular venous distention, clinical heart failure is highly unlikely, making an echocardiogram unnecessary. Prescribing a daily loop diuretic is inappropriate because this specific type of edema is not driven by total body fluid retention. Reducing the amlodipine dose or adding an ACE inhibitor helps normalize the capillary hydrostatic pressure and typically resolves the edema. Leg elevation alone is usually insufficient.

According to the GOLD guidelines, this patient is classified as Group B because they have a high symptom burden, indicated by an mMRC score of 2, but a low exacerbation risk with zero recent exacerbations. The recommended initial pharmacological treatment for Group B is a combination of a LAMA and a LABA. Option B is incorrect because short-acting bronchodilators alone are insufficient for maintenance therapy in highly symptomatic patients. Option C is incorrect because inhaled corticosteroids are not indicated for initial therapy in Group B patients without a history of frequent exacerbations or elevated eosinophils. Option D is incorrect because while LAMA monotherapy was previously acceptable for some Group B patients, updated guidelines now prioritize LAMA and LABA combination therapy to better manage significant dyspnea and improve lung function.